Filing Details
- Accession Number:
- 0001144204-15-058985
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-10-09 19:59:14
- Reporting Period:
- 2015-10-07
- Filing Date:
- 2015-10-09
- Accepted Time:
- 2015-10-09 19:59:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1609351 | Spark Therapeutics Inc. | ONCE | Biological Products, (No Disgnostic Substances) (2836) | 462654405 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1590102 | Anand Mehra | Sofinnova Ventures 3000 Sand Hill Road, 4-250 Menlo Park CA 94025 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-10-07 | 85,502 | $45.56 | 2,033,074 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2015-10-07 | 153,008 | $46.23 | 1,880,066 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2015-10-07 | 13,402 | $47.14 | 1,866,664 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2015-10-08 | 120,593 | $44.38 | 1,746,071 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2015-10-08 | 145,723 | $45.27 | 1,600,348 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2015-10-08 | 11,316 | $46.38 | 1,589,032 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (6) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.80, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.96, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.03 to $46.85, inclusive.
- The securities are owned directly by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII"), the general partner of SVP VIII, and Anand Mehra, a director of the Issuer, James I. Healy, Srinivas Akkaraju, and Michael Powell, the managing members of SM VIII, may be deemed to have shared voting and dispositive power over the shares owned by SVP VIII. Such persons and entities disclaim beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.